Antidepressant studies in Parkinson's disease: A review and meta-analysis

被引:125
作者
Weintraub, D
Morales, KH
Moberg, PJ
Bilker, WB
Balderston, C
Duda, JE
Katz, IR
Stern, MB
机构
[1] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[3] Philadelphia Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA
[4] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA
[5] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
关键词
Parkinson's disease; depression; antidepressive agent; treatment; effect size; meta-analysis;
D O I
10.1002/mds.20555
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta-analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and anti depressant use in PD, controlled treatment research has been almost nonexistent. Meta-analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. (C)005 Movement Disorder Society.
引用
收藏
页码:1161 / 1169
页数:9
相关论文
共 69 条
[1]
Rational treatment choices for non-major depressions in primary care - An evidence-based review [J].
Ackermann, RT ;
Williams, JW .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (04) :293-301
[2]
Alexopoulos G S, 2001, Postgrad Med, VSpec No Pharmacotherapy, P1
[3]
SELEGILINE IN DENOVO PARKINSONIAN-PATIENTS - THE FRENCH SELEGILINE MULTICENTER TRIAL (FSMT) [J].
ALLAIN, H ;
COUGNARD, J ;
NEUKIRCH, HC .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 :73-78
[4]
ANDERSEN J, 1980, ACTA NEUROL SCAND, V62, P210
[5]
ANDERSEN J, 1975, DEPRESSIVE TILSTANDE
[6]
[Anonymous], 1984, Meta-analysis procedures for social research
[7]
[Anonymous], J SEROTONIN RES
[8]
Årsland D, 2000, NORD J PSYCHIAT, V54, P411
[9]
DEPRENYL EFFECTS ON LEVODOPA PHARMACODYNAMICS, MOOD, AND FREE-RADICAL SCAVENGING [J].
BARONTI, F ;
DAVIS, TL ;
BOLDRY, RC ;
MOURADIAN, MM ;
CHASE, TN .
NEUROLOGY, 1992, 42 (03) :541-544
[10]
AN INVENTORY FOR MEASURING DEPRESSION [J].
BECK, AT ;
ERBAUGH, J ;
WARD, CH ;
MOCK, J ;
MENDELSOHN, M .
ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&